Please assess the completion status of the following clinical trial:

Trial Title: A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. At least 18 years of age.~2. Clinical diagnosis of Systemic Lupus Erythematosus (SLE) by ACR criteria.~3. Active SLE disease.~4. Autoantibody-positive.~5. On stable SLE treatment regimen which may include corticosteroids (for example, prednisone), antimalarial (for example, hydroxychloroquine) and/or immunosuppressants (for example, azathioprine, methotrexate, mycophenolate, etc.)~Exclusion Criteria:~1. Pregnant or nursing.~2. Have received treatment with any B cell targeted therapy (for example, rituximab or belimumab).~3. Have received treatment an investigational biological agent in the past year.~4. Have received intravenous (IV) cyclophosphamide within 90 days of Day 0.~5. Have severe active lupus kidney disease.~6. Have severe active central nervous system (CNS) lupus.~7. Have required management of acute or chronic infections within the past 60 days.~8. Have current drug or alcohol abuse or dependence.~9. Have a positive test for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.~10. Have a history of hypersensitivity reactions to contrast agents or biological medicines.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo plus standard therapy (Type: PLACEBO_COMPARATOR): Placebo SC plus standard therapy; placebo administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo subjects who opt to participate will receive belimumab 200 mg SC weekly for an additional 6-months.
- Belimumab 200 mg SC plus standard therapy (Type: EXPERIMENTAL): Belimumab 200 mg SC plus standard therapy; belimumab administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, subjects who opt to participate will continue on the same dose of belimumab for an additional 6-months.

Based on this trial design, predict the completion outcome and termination type (if applicable).